BLB&B Advisors LLC held its stake in Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,343 shares of the biopharmaceutical company’s stock at the end of the second quarter. BLB&B Advisors LLC’s holdings in Shire PLC were worth $234,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. HPM Partners LLC bought a new stake in shares of Shire PLC during the first quarter worth approximately $1,534,000. Laurion Capital Management LP bought a new stake in shares of Shire PLC during the first quarter worth approximately $10,611,000. Vanguard Group Inc. increased its stake in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares during the last quarter. Gabelli Funds LLC increased its stake in shares of Shire PLC by 1,000.0% in the first quarter. Gabelli Funds LLC now owns 16,500 shares of the biopharmaceutical company’s stock worth $2,875,000 after buying an additional 15,000 shares during the last quarter. Finally, Northern Capital Management LLC increased its stake in shares of Shire PLC by 8.1% in the first quarter. Northern Capital Management LLC now owns 14,255 shares of the biopharmaceutical company’s stock worth $2,484,000 after buying an additional 1,070 shares during the last quarter. Institutional investors and hedge funds own 21.06% of the company’s stock.

Shire PLC (SHPG) traded up 2.38% during midday trading on Friday, hitting $164.03. The company had a trading volume of 2,290,465 shares. The firm has a market cap of $48.86 billion, a PE ratio of 168.24 and a beta of 1.60. Shire PLC has a 52-week low of $158.54 and a 52-week high of $209.22.

Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.22 by $0.41. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The firm had revenue of $3.57 billion for the quarter. During the same period in the previous year, the company posted $2.12 EPS. Shire PLC’s quarterly revenue was up 109.0% compared to the same quarter last year. On average, analysts forecast that Shire PLC will post $14.81 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/07/23/shire-plc-shpg-position-held-by-blbb-advisors-llc.html.

SHPG has been the topic of a number of recent research reports. Royal Bank Of Canada set a $221.00 target price on Shire PLC and gave the stock a “buy” rating in a research note on Thursday, May 18th. Jefferies Group LLC set a $239.00 target price on Shire PLC and gave the stock a “buy” rating in a research note on Thursday, April 20th. Stifel Nicolaus lowered their target price on Shire PLC from $250.00 to $245.00 and set a “buy” rating on the stock in a research note on Friday, June 9th. Cantor Fitzgerald set a $222.00 target price on Shire PLC and gave the stock a “buy” rating in a research note on Saturday, July 1st. Finally, ValuEngine upgraded Shire PLC from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $227.45.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.